Meridian Bioscience, Inc. (NASDAQ:VIVO – Get Rating) saw strong trading volume on Wednesday . 960,729 shares traded hands during mid-day trading, an increase of 106% from the previous session’s volume of 467,327 shares.The stock last traded at $33.94 and had previously closed at $33.76.
Analyst Upgrades and Downgrades
VIVO has been the topic of several research analyst reports. StockNews.com cut Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, November 19th. William Blair reissued a “market perform” rating on shares of Meridian Bioscience in a research report on Friday, November 25th.
Meridian Bioscience Price Performance
The firm has a market capitalization of $1.49 billion, a PE ratio of 34.80 and a beta of 0.26. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.46 and a current ratio of 3.63. The stock has a fifty day moving average price of $32.82 and a 200-day moving average price of $32.45.
Hedge Funds Weigh In On Meridian Bioscience
Several hedge funds have recently modified their holdings of the stock. Envestnet Asset Management Inc. boosted its position in Meridian Bioscience by 0.8% in the second quarter. Envestnet Asset Management Inc. now owns 41,308 shares of the company’s stock valued at $1,257,000 after buying an additional 341 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new position in Meridian Bioscience during the second quarter valued at $2,668,000. Texas Permanent School Fund boosted its holdings in Meridian Bioscience by 2.0% in the second quarter. Texas Permanent School Fund now owns 31,495 shares of the company’s stock valued at $958,000 after purchasing an additional 626 shares during the last quarter. Arizona State Retirement System grew its position in Meridian Bioscience by 6.0% during the 2nd quarter. Arizona State Retirement System now owns 11,800 shares of the company’s stock worth $359,000 after purchasing an additional 664 shares during the period. Finally, Exchange Traded Concepts LLC raised its stake in shares of Meridian Bioscience by 1.3% during the 4th quarter. Exchange Traded Concepts LLC now owns 55,898 shares of the company’s stock valued at $1,856,000 after buying an additional 732 shares during the last quarter. Institutional investors and hedge funds own 89.72% of the company’s stock.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.
- Get a free copy of the StockNews.com research report on Meridian Bioscience (VIVO)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.